Clear Search

Showing 7 results for “Rovin BH”.

August 2023

Effect of Belimumab on Kidney-related Outcomes in Patients with Lupus Nephritis: Post Hoc Subgroup Analyses of the Phase 3 BLISS-LN Trial

Nephrol Dial Transplant. 2023 doi: 10.1093/ndt/gfad167 Epub ahead of print.

These data highlight the consistent benefit of belimumab versus placebo, combined with standard therapy, on kidney outcomes in both newly diagnosed and relapsed patients, and regardless of the use of GC pulses at induction.


May 2023

Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process with RISE Registry Data Review

Arthritis Care Res (Hoboken). 2023 doi: 10.1002/acr.25143 Epub ahead of print

The first ACR quality measures for SLE selected by Bartels, et al. use a rigorous Delphi process, and include recommendations on hydroxychloroquine, glucocorticoid reduction and kidney monitoring.


November 2022

Safety and Efficacy of Belimumab in Patients with Lupus Nephritis

Clin J Am Soc Nephrol. 2022;17:1620–1630 doi: 10.2215/CJN.02520322

This 28-week, open-label extension of BLISS-LN found no new safety signals and maintained efficacy with belimumab, in patients with lupus nephritis.


March 2022
November 2021
October 2021

Two-Year, Randomised, Controlled Trial of Belimumab in Lupus Nephritis

N Engl J Med. 2020;383(12):1117–28.

LN occurs in 25–60% of patients with SLE. However, patients with LN are often excluded from clinical trials of SLE therapies.